Study of Novel Types of Familial Diabetes Insipidus

The recruitment status of this study is unknown because the information has not been verified recently.

Verified February 2006 by Office of Rare Diseases (ORD).
Recruitment status was Active, not recruiting

Sponsor:

Collaborator:

Northwestern University

Information provided by:

Office of Rare Diseases (ORD)

ClinicalTrials.gov Identifier:

NCT00004364

First received: October 18, 1999

Last updated: February 21, 2006

Last verified: February 2006

History of Changes

Purpose

OBJECTIVES:

I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.

Condition	Intervention
Diabetes Insipidus	Drug: desmopressin


Study Type:	Observational
Study Design:	Primary Purpose: Screening

Resource links provided by NLM:

Genetics Home Reference related topics: neurohypophyseal diabetes insipidus

MedlinePlus related topics: Diabetes Insipidus

Drug Information available for: Desmopressin

U.S. FDA Resources

Further study details as provided by Office of Rare Diseases (ORD):


Estimated Enrollment:	5
Study Start Date:	December 1995

Detailed Description:

PROTOCOL OUTLINE: Participants undergo a series of tests to determine the presence, absence, cause, natural history, clinical status, and mode of inheritance of their type of diabetes insipidus (DI). The studies include measurements of basal fluid intake and urine output, plasma vasopressin during standard fluid deprivation or waterload/saline infusion tests, and changes in water balance during a therapeutic trial of DDAVP. If clinically indicated, echocardiograms and assays of plasma catecholes and renin are also completed.

Linkage analysis is performed for all participants; kindreds with the Marfan-like syndrome are also studied for the fibrillin-1 genotype.

Participants determined to have DI are treated with desmopressin for 2 days.

Eligibility


Ages Eligible for Study:	6 Months to 70 Years (Child, Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Familial diabetes insipidus (DI) in atypical or novel form, e.g.: Dipsogenic DI Neurohypophyseal DI
Affected and unaffected members of kindreds eligible

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004364

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Northwestern University

Investigators


Study Chair:	Gary L. Robertson	Northwestern University

More Information


ClinicalTrials.gov Identifier:	NCT00004364 History of Changes
Other Study ID Numbers:	199/11939 NU-570
Study First Received:	October 18, 1999
Last Updated:	February 21, 2006
Health Authority:	United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):


diabetes insipidus endocrine disorders rare disease

Additional relevant MeSH terms:


Diabetes Insipidus Kidney Diseases Urologic Diseases Pituitary Diseases Endocrine System Diseases Deamino Arginine Vasopressin Arginine Vasopressin	Hemostatics Coagulants Antidiuretic Agents Natriuretic Agents Physiological Effects of Drugs Vasoconstrictor Agents

ClinicalTrials.gov processed this record on September 27, 2016

To Top